Annovis Bio (ANVS)
(Delayed Data from NYSE)
$7.69 USD
-0.56 (-6.79%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $7.68 -0.01 (-0.13%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.69 USD
-0.56 (-6.79%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $7.68 -0.01 (-0.13%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Zacks News
Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam
by Zacks Equity Research
Cassava (SAVA) reports top-line data from an interim analysis of the on-going study evaluating simufilam in patients with mild-to-moderate Alzheimer's disease.
Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock Down
by Zacks Equity Research
Biogen's (BIIB) new Alzheimer's drug, Aduhelm, can bring in huge revenues, if successfully commercialized.
Cassava (SAVA) Stock Up on Alzheimer's Candidate Update
by Zacks Equity Research
Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.
Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day
3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug
by Kinjel Shah
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.